Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
74 hedge funds and large institutions have $127M invested in Unity Biotechnology in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 14 closing their positions.
12,100% more call options, than puts
Call options by funds: $122K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 23
0.14% less ownership
Funds ownership: 4.74% → 4.6% (-0.14%)
6% less funds holding
Funds holding: 79 → 74 (-5)
19% less capital invested
Capital invested by funds: $157M → $127M (-$30.1M)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.67M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$935K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$824K |
| 4 |
Renaissance Technologies
New York
|
+$721K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$286K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.32M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.58M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.08M |
| 4 |
Morgan Stanley
New York
|
-$1.01M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$389K |
UBX Hedge Fund Activity: Q1 2020 in Review
74 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q1 2020, worth a combined $127M — down 19% from $157M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of UBX and 10 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 23 added.
The largest buyer was Fidelity Investments, adding an estimated $5.67M. The largest seller was Millennium Management, cutting an estimated $2.32M.
- 74 institutional investors held Unity Biotechnology (UBX) as of Q1 2020, down from 79 in Q4 2019.
- Funds reported $127M of Unity Biotechnology stock for Q1 2020, down 19% quarter-over-quarter.
- 10 funds opened new Unity Biotechnology positions in Q1 2020 and 14 closed out, a net change of -4 holders.
- The largest Unity Biotechnology buyer in Q1 2020 was Fidelity Investments, an estimated $5.67M added.
- The largest Unity Biotechnology seller in Q1 2020 was Millennium Management, an estimated $2.32M sold.
Based on aggregated 13F filings for Q1 2020.